Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind randomized controlled trial of intranasal PrEP-001 in asthmatic adults challenged with human rhinovirus 16
2015-004042-26Phase 2Completed
- Sponsor
- hVIVO
- Start
- Oct 2015
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma and rhinoviral infection comparing PrEP-001 intranasal with Placebo intranasal (2 arms). Primary endpoint: AUC of total symptom score post viral challenge. Started Oct 2015; status: completed.
02
Drugs
polyinosine-polycytidylic acid
03
Conditions
asthmarhinoviral infection
Beyond the preview
Go deeper on 2015-004042-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004042-26.